Anne P. O'Dea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne P. O'Dea has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew K. Godwin
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA
19 shared publications - Coralia Bueno
Medical Oncology Department, Hospital Universitario Infanta Cristina, Parla, Spain
19 shared publications - Enrique L. Álvarez
Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, Spain
19 shared publications - Fernando Moreno
Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain
19 shared publications - Henry Gomez
INEN—Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
19 shared publications - Isabel Echavarría
Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Madrid, Spain
19 shared publications
Latest Publications
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by pathologic response
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by pathologic response
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Pathologic response categories
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Pathologic response categories
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data